Medical and Psychiatric Consultation for Patients Considering State-Regulated Psilocybin Services: A Risk-Reduction Model and Two Illustrative Cases
This paper introduces the PEACE consultation model, which supports patients considering state-regulated psilocybin services through risk-reduction planning and longitudinal care, as illustrated by two complex cases demonstrating the challenges of real-world application and the necessity of ongoing clinical follow-up.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
In the last few years, a quiet shift has begun in how some people approach mental health. For decades, a naturally occurring compound found in certain mushrooms, known as psilocybin, was strictly prohibited and studied only in highly controlled laboratory settings. Recently, however, the state of Oregon became the first place in the United States to create a legal framework allowing trained facilitators to guide adults through supervised experiences with this substance. This new system is designed to help people with conditions like depression, anxiety, and addiction. Yet, a significant gap has emerged: the people seeking these services often have complex medical histories and take multiple medications, a group that was largely excluded from the earlier scientific trials. While the trials showed promise, they did not test whether the treatment was safe or effective for patients with complicated lives, multiple diagnoses, or difficult pasts. As more people step into this new legal space, doctors are left asking how to guide them safely when the rules of the laboratory do not fully apply to the real world.
To address this uncertainty, a team of clinicians at Oregon Health & Science University developed a consultation model called PEACE, which stands for Psilocybin Education and Assessment Collaborative for Excellence. This service does not provide the mushrooms or lead the sessions; instead, it acts as a bridge between a patient's existing medical care and the new state-regulated services. The team, consisting of psychiatrists and family medicine doctors, meets with individuals to review their full medical and psychiatric history, assess their risks, and help them make informed decisions. They look for factors that might make the experience dangerous, such as a history of psychosis or certain heart conditions, and they help patients plan for what happens before, during, and after the experience. The goal is not to stop people from trying the treatment, but to ensure that if they do, they are supported by a safety net that understands their unique vulnerabilities.
The researchers illustrated how this model works by sharing the stories of two patients who used the service. The first was a forty-one-year-old man struggling with alcohol use disorder. Before seeing the team, he had faced severe consequences from his drinking, including emergency room visits and a near-fatal overdose. He was also taking several medications for depression and high blood pressure. The consultants helped him understand that his current medications might interfere with the effects of the psilocybin and that stopping them abruptly could be risky. He worked with his primary doctor to adjust his medications and then underwent two supervised sessions, each involving a dose of fifty milligrams of psilocybin. Initially, he felt a sense of relief and a break in the rigid patterns of his addiction. However, his recovery was not a straight line. Months later, his drinking returned, and he eventually stopped drinking entirely, only to later take a large dose of psilocybin on his own without any medical guidance. This unsupervised experience left him feeling disoriented and isolated. He returned to the consultation team, who helped him process the difficult emotions and integrate the experience into his life. Over time, he achieved long-term sobriety, demonstrating that recovery often involves setbacks and requires ongoing support rather than a single magical fix.
The second story involved a seventy-nine-year-old woman with a history of major depression who had been stable on antidepressant medication for twenty years. She wanted to stop taking her medication because of side effects and hoped that psilocybin could help her maintain her mental health without drugs. The team assessed her history and noted that while she was currently stable, stopping her medication carried a high risk of her depression returning. They helped her create a slow, careful plan to reduce her medication under the supervision of her own doctor. She then attended two supervised sessions. The first was emotionally challenging, bringing up deep grief and family trauma, while the second felt joyful and brought her a sense of renewal. For a few months, she felt better than she had in years, with her depression in remission and her physical side effects gone. But then, about three months after her second session, her mood began to shift. Irritability turned into deep sadness, and she eventually experienced a severe depressive episode. Because she had a connection with the consultation team, she was able to return for care. The team stepped in to manage her medications and provide therapy, helping her stabilize and eventually return to a state of wellness. Her journey showed that even when a treatment works beautifully at first, the effects can fade or change, and long-term medical support is often necessary to sustain the benefits.
These two cases highlight a crucial reality about bringing psychedelic treatments into everyday healthcare: early success does not guarantee long-term recovery. The patients in the original scientific trials were carefully selected to be healthy and free of complex medical issues, which makes their results hard to apply to the general population. In the real world, people have complicated histories, take many different drugs, and face unpredictable life events. The PEACE model suggests that for these individuals, the most important part of the process may not be the session itself, but the care that surrounds it. By offering individualized risk assessment, helping patients navigate medication changes, and providing support when things go wrong, this approach helps integrate a powerful new tool into the existing system of medical care. The findings suggest that while psilocybin holds significant potential, its safe and effective use for complex patients depends on a framework of continuous, coordinated care that extends far beyond the moment of the experience.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.